Amicus Therapeutics Inc
NASDAQ:FOLD

Watchlist Manager
Amicus Therapeutics Inc Logo
Amicus Therapeutics Inc
NASDAQ:FOLD
Watchlist
Price: 9.66 USD 1.68% Market Closed
Market Cap: 2.9B USD
Have any thoughts about
Amicus Therapeutics Inc?
Write Note

Intrinsic Value

The intrinsic value of one FOLD stock under the Base Case scenario is 11.64 USD. Compared to the current market price of 9.66 USD, Amicus Therapeutics Inc is Undervalued by 17%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

FOLD Intrinsic Value
11.64 USD
Undervaluation 17%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Amicus Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for FOLD cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about FOLD?
Bearish
Neutral
Bullish

Fundamental Analysis

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Amicus Therapeutics Inc

Provide an overview of the primary business activities
of Amicus Therapeutics Inc.

What unique competitive advantages
does Amicus Therapeutics Inc hold over its rivals?

What risks and challenges
does Amicus Therapeutics Inc face in the near future?

Has there been any significant insider trading activity
in Amicus Therapeutics Inc recently?

Summarize the latest earnings call
of Amicus Therapeutics Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Amicus Therapeutics Inc.

Provide P/S
for Amicus Therapeutics Inc.

Provide P/E
for Amicus Therapeutics Inc.

Provide P/OCF
for Amicus Therapeutics Inc.

Provide P/FCFE
for Amicus Therapeutics Inc.

Provide P/B
for Amicus Therapeutics Inc.

Provide EV/S
for Amicus Therapeutics Inc.

Provide EV/GP
for Amicus Therapeutics Inc.

Provide EV/EBITDA
for Amicus Therapeutics Inc.

Provide EV/EBIT
for Amicus Therapeutics Inc.

Provide EV/OCF
for Amicus Therapeutics Inc.

Provide EV/FCFF
for Amicus Therapeutics Inc.

Provide EV/IC
for Amicus Therapeutics Inc.

Show me price targets
for Amicus Therapeutics Inc made by professional analysts.

What are the Revenue projections
for Amicus Therapeutics Inc?

How accurate were the past Revenue estimates
for Amicus Therapeutics Inc?

What are the Net Income projections
for Amicus Therapeutics Inc?

How accurate were the past Net Income estimates
for Amicus Therapeutics Inc?

What are the EPS projections
for Amicus Therapeutics Inc?

How accurate were the past EPS estimates
for Amicus Therapeutics Inc?

What are the EBIT projections
for Amicus Therapeutics Inc?

How accurate were the past EBIT estimates
for Amicus Therapeutics Inc?

Compare the revenue forecasts
for Amicus Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Amicus Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Amicus Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Amicus Therapeutics Inc compared to its peers.

Compare the P/E ratios
of Amicus Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Amicus Therapeutics Inc with its peers.

Analyze the financial leverage
of Amicus Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for Amicus Therapeutics Inc.

Provide ROE
for Amicus Therapeutics Inc.

Provide ROA
for Amicus Therapeutics Inc.

Provide ROIC
for Amicus Therapeutics Inc.

Provide ROCE
for Amicus Therapeutics Inc.

Provide Gross Margin
for Amicus Therapeutics Inc.

Provide Operating Margin
for Amicus Therapeutics Inc.

Provide Net Margin
for Amicus Therapeutics Inc.

Provide FCF Margin
for Amicus Therapeutics Inc.

Show all solvency ratios
for Amicus Therapeutics Inc.

Provide D/E Ratio
for Amicus Therapeutics Inc.

Provide D/A Ratio
for Amicus Therapeutics Inc.

Provide Interest Coverage Ratio
for Amicus Therapeutics Inc.

Provide Altman Z-Score Ratio
for Amicus Therapeutics Inc.

Provide Quick Ratio
for Amicus Therapeutics Inc.

Provide Current Ratio
for Amicus Therapeutics Inc.

Provide Cash Ratio
for Amicus Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for Amicus Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for Amicus Therapeutics Inc?

What is the current Free Cash Flow
of Amicus Therapeutics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Amicus Therapeutics Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Amicus Therapeutics Inc

Current Assets 498.5m
Cash & Short-Term Investments 249.8m
Receivables 98.1m
Other Current Assets 150.6m
Non-Current Assets 288.1m
PP&E 53.6m
Intangibles 215.8m
Other Non-Current Assets 18.7m
Current Liabilities 158.1m
Accounts Payable 13.5m
Accrued Liabilities 144.7m
Non-Current Liabilities 449.6m
Long-Term Debt 389.5m
Other Non-Current Liabilities 60.1m
Efficiency

Earnings Waterfall
Amicus Therapeutics Inc

Revenue
493.7m USD
Cost of Revenue
-49.4m USD
Gross Profit
444.2m USD
Operating Expenses
-429.8m USD
Operating Income
14.4m USD
Other Expenses
-119.1m USD
Net Income
-104.7m USD

Free Cash Flow Analysis
Amicus Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

Amicus Therapeutics achieved a remarkable $142 million in Q3 revenue, a 37% surge year-over-year, driven by Galafold's $120 million sales, up 19%. The company raised its full-year revenue growth forecast to 30-32%, reflecting strong demand in treating Fabry disease, with Galafold's annual growth now projected at 16-18%. The launch of Pombiliti and Opfolda for Pompe disease is also robust, with expected sales between $69-71 million. Non-GAAP profitability is confirmed for the year, alongside effective expense management. Overall, the foundation for ongoing growth appears solid as patient identification improves, particularly in underserved markets.

What is Earnings Call?
Fundamental Scores

FOLD Profitability Score
Profitability Due Diligence

Amicus Therapeutics Inc's profitability score is 32/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
ROIC is Increasing
Exceptional Revenue Growth Forecast
Positive 3-Years Revenue Growth
32/100
Profitability
Score

Amicus Therapeutics Inc's profitability score is 32/100. The higher the profitability score, the more profitable the company is.

FOLD Solvency Score
Solvency Due Diligence

Amicus Therapeutics Inc's solvency score is 32/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Positive Net Debt
High D/E
32/100
Solvency
Score

Amicus Therapeutics Inc's solvency score is 32/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

FOLD Price Targets Summary
Amicus Therapeutics Inc

Wall Street analysts forecast FOLD stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for FOLD is 18.11 USD with a low forecast of 14.14 USD and a high forecast of 22.05 USD.

Lowest
Price Target
14.14 USD
46% Upside
Average
Price Target
18.11 USD
87% Upside
Highest
Price Target
22.05 USD
128% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for FOLD?

Click here to dive deeper.

Dividends

Amicus Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for FOLD is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

FOLD Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

FOLD News

Other Videos

Profile

Amicus Therapeutics Inc Logo
Amicus Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

2.9B USD

Dividend Yield

0%

Description

Amicus Therapeutics, Inc. operates as a biotechnology company. The company is headquartered in Philadelphia, Pennsylvania and currently employs 496 full-time employees. The company went IPO on 2007-05-31. The firm's portfolio is Galafold (migalastat), which is the approved oral precision medicine for people living with Fabry disease. Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A (alpha-Gal A) enzyme in patients with genetic variants. Migalastat is approved under the trade name Galafold in the United States, European Union, United Kingdom and Japan. Its biologics program in its pipeline is Amicus Therapeutics GAA (AT-GAA), which is a clinical-stage treatment paradigm for Pompe disease. Pompe disease is a lysosomal disorder (LD) from deficiency in an enzyme, GAA. AT-GAA consists of a uniquely engineered rhGAA enzyme, ATB200, or cipaglucosidase alfa, with an optimized carbohydrate structure to enhance lysosomal uptake, administered in combination with AT2221 (miglustat) that functions as an enzyme stabilizer.

Contact

PENNSYLVANIA
PHILADELPHIA
3675 Market Street
+12159217600.0
www.amicusrx.com

IPO

2007-05-31

Employees

496

Officers

CEO, President & Director
Mr. Bradley L. Campbell M.B.A.
Chief Financial Officer
Mr. Simon Nicolas Reade Harford
Chief Legal Officer & Corporate Secretary
Ms. Ellen S. Rosenberg
Chief People Officer
Mr. David M. Clark
Chief Development Officer
Dr. Jeffrey P. Castelli Ph.D.
Chief Accounting Officer & Controller
Ms. Samantha Prout
Show More
Chief Science Officer
Dr. Jill Weimer Ph.D.
Senior Director of Investor Relations
Andrew Faughnan
Global Chief Compliance & Risk Officer
Mr. Patrik S. Florencio Esq.
Head of Global Corporate Communications
Ms. Diana Moore
Show Less

See Also

Discover More
What is the Intrinsic Value of one FOLD stock?

The intrinsic value of one FOLD stock under the Base Case scenario is 11.64 USD.

Is FOLD stock undervalued or overvalued?

Compared to the current market price of 9.66 USD, Amicus Therapeutics Inc is Undervalued by 17%.

Back to Top